Cargando…

Comment on: “Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy” by Zhou et al.

Detalles Bibliográficos
Autor principal:	Chen, Tai‐Heng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567159/ https://www.ncbi.nlm.nih.gov/pubmed/32716121 http://dx.doi.org/10.1002/jcsm.12607

Ejemplares similares

The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
por: Zhou, Haiyan, et al.
Publicado: (2020)

Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
por: Zhou, Haiyan, et al.
Publicado: (2020)

A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
por: Keil, Jeffrey M, et al.
Publicado: (2014)

High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts
por: Wijaya, Yogik Onky Silvana, et al.
Publicado: (2022)

Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment
por: Sintusek, Palittiya, et al.
Publicado: (2016)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
por: Biliouris, Konstantinos, et al.
Publicado: (2018)

Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
por: Müschen, Lars Hendrik, et al.
Publicado: (2021)

Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
por: Catapano, Francesco, et al.
Publicado: (2016)

Letter to the Editor in Response to Zhou et al
por: Troth, Sean, et al.
Publicado: (2021)

Antisense-based therapy for the treatment of spinal muscular atrophy
por: Rigo, Frank, et al.
Publicado: (2012)

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
por: Paris, Alessio, et al.
Publicado: (2022)

Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular Atrophy
por: Mitrpant, Chalermchai, et al.
Publicado: (2013)

Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice
por: Strathmann, Eike A., et al.
Publicado: (2018)

Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)
por: Harish, Pradeep, et al.
Publicado: (2019)

Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy
por: Hammond, Suzan M., et al.
Publicado: (2022)

Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy
por: Li, Yang-Jean, et al.
Publicado: (2020)

It’s time to measure disability in spinal muscular atrophy
por: Trabacca, Antonio, et al.
Publicado: (2022)

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
por: Aoki, Yoshitsugu, et al.
Publicado: (2013)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy
por: Chen, Tai-Heng
Publicado: (2020)

Response to Zhou et al. regarding Cardiac injury prediction and lymphocyte immunity and inflammation analysis in hospitalized patients with coronavirus disease 2019 (COVID-19)
por: Tan, Alexander, et al.
Publicado: (2021)

Comment on: A novel dysferlin-mutant pseudoexon bypassed with antisense oligonucleotides
por: Kergourlay, Virginie, et al.
Publicado: (2015)

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
por: van Deutekom, Judith, et al.
Publicado: (2023)

The Authors reply: Comment on: “Experimental ischaemic stroke induces transient cardiac atrophy” by Veltkamp et al.
por: Veltkamp, Roland, et al.
Publicado: (2021)

Reply to the comment by Osuka et al.
por: Endo, Akira, et al.
Publicado: (2020)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Reply to comment on: A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides
por: Dominov, Janice A, et al.
Publicado: (2015)

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
por: Scaglioni, Dominic, et al.
Publicado: (2021)

Reply to Aljabali et al. Comment on “Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213”
por: Abdelazeem, Basel, et al.
Publicado: (2022)

Effects of combinations of gapmer antisense oligonucleotides on the target reduction
por: Yanagidaira, Mitsugu, et al.
Publicado: (2023)

Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy
por: Shabanpoor, Fazel, et al.
Publicado: (2017)

Response to Zhou and Robinson
por: Betel, Doron, et al.
Publicado: (2015)

Reply to Shao and Zhou
por: Gagelmann, Nico, et al.
Publicado: (2022)

Reply to Wang and Zhou
por: Jandl, Katharina, et al.
Publicado: (2023)

Improvement of muscular atrophy by AAV–SaCas9-mediated myostatin gene editing in aged mice
por: Weng, Shaoting, et al.
Publicado: (2020)

Reply to Chacko et al.: Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy
por: LoMauro, Antonella, et al.
Publicado: (2020)

Comment on: “Aldehyde dehydrogenases contribute to skeletal muscle homeostasis in healthy, aging, and Duchenne muscular dystrophy patients” by Etienne et al.
por: Campos, Juliane C., et al.
Publicado: (2020)

A comment on Mokabel et al. (2017)
por: Basu, Saurav
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_osc5ivab5cksl3kkrnf0l977ho